Compound 2 (Figure 2) exhibited potent IDO1 inhibition (IC50 = 5 nM) and demonstrated significant anti-tumor activity in vivo models of Lewis lung carcinoma (LL2) and hepatocellular carcinoma (Hepa1-6), with minimal toxicity (Pan et al., 2020). Here, IDO1 is linked to neoplasm.